This menu provides the list of EV miRNAs identified by high-throughput analyses.

Search:
Superdomain: All Prokaryote Eukaryote
Filter datasets:
  - "Sample type" indicates the source from which EVs originated (e.g. B cell, serum).
  - "Sample status" indicates the condition of the source from which EVs originated (e.g. Normal, miR-146a-treated, Patients of hernia).
Maximum false positive rate (FPR): Maximum true positive rate (TPR):
  - FPR is the probability that an absent miRNA accidently have higher intensity than that miRNA.
  - TPR is the percentile of miRNA among the present miRNAs.
    Please see user manual in the contact us/help menu for detail.
Number of molecules in one page:

The downloaded CSV file is not exactly the same as the displayed table. Opening CSV file with Excel can impair its content.

Since there are multiple primers in the microarray, the same miRNA can have several FPR and TPR values.

Mature name miRBase accession FPR TPR Publication Orthologous group Identification count
All / Prokaryote / Eukaryote
(FPR<0.05,TPR<0.5)
hsa-miR-548a-5pMIMAT0004803 1.3e-7 0.0e+0Exosomes derived from hypoxic leukemia cells enhance tube formation in endothelial cells.
J Biol Chem. 2013 Nov 29;288(48):34343-51. doi: 10.1074/jbc.M113.480822. Epub 2013 Oct 16.		MIPF0000317_143 / 0 / 43
hsa-miR-548a-5pMIMAT0004803 0.0e+0 1.1e-1Circulating exosomal microRNAs as biomarkers of colon cancer.
PLoS One. 2014 Apr 4;9(4):e92921. doi: 10.1371/journal.pone.0092921. eCollection 2014.		MIPF0000317_143 / 0 / 43
hsa-miR-548a-5pMIMAT0004803 5.5e-3 0.0e+0Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1.
Blood. 2014 Oct 15. pii: blood-2014-05-576116.		MIPF0000317_143 / 0 / 43
hsa-miR-548a-5pMIMAT0004803 3.8e-3 0.0e+0Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1.
Blood. 2014 Oct 15. pii: blood-2014-05-576116.		MIPF0000317_143 / 0 / 43
hsa-miR-548a-5pMIMAT0004803 9.7e-3 0.0e+0Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1.
Blood. 2014 Oct 15. pii: blood-2014-05-576116.		MIPF0000317_143 / 0 / 43
hsa-miR-548a-5pMIMAT0004803 9.3e-4 9.3e-4Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1.
Blood. 2014 Oct 15. pii: blood-2014-05-576116.		MIPF0000317_143 / 0 / 43
hsa-miR-548a-5pMIMAT0004803 1.1e-3 1.1e-3Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1.
Blood. 2014 Oct 15. pii: blood-2014-05-576116.		MIPF0000317_143 / 0 / 43
hsa-miR-548a-5pMIMAT0004803 6.6e-9 0.0e+0Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1.
Blood. 2014 Oct 15. pii: blood-2014-05-576116.		MIPF0000317_143 / 0 / 43
hsa-miR-548a-5pMIMAT0004803 4.4e-5 3.8e-1Plasma-derived exosome characterization reveals a distinct microRNA signature in long duration Type 1 diabetes.
Sci Rep. 2017 Jul 20;7(1):5998. doi: 10.1038/s41598-017-05787-y.		MIPF0000317_143 / 0 / 43
hsa-miR-548a-5pMIMAT0004803 4.0e-7 3.4e-1Plasma-derived exosome characterization reveals a distinct microRNA signature in long duration Type 1 diabetes.
Sci Rep. 2017 Jul 20;7(1):5998. doi: 10.1038/s41598-017-05787-y.		MIPF0000317_143 / 0 / 43
hsa-miR-548a-5pMIMAT0004803 4.6e-5 0.0e+0Replenishing exosomes from older bone marrow stromal cells with miR-340 inhibits myeloma-related angiogenesis.
Blood Adv. 2017 May 16;1(13):812-823. doi: 10.1182/bloodadvances.2016003251. eCollection 2017 May 23.		MIPF0000317_143 / 0 / 43
hsa-miR-548a-5pMIMAT0004803 1.8e-2 1.8e-2Replenishing exosomes from older bone marrow stromal cells with miR-340 inhibits myeloma-related angiogenesis.
Blood Adv. 2017 May 16;1(13):812-823. doi: 10.1182/bloodadvances.2016003251. eCollection 2017 May 23.		MIPF0000317_143 / 0 / 43
[1]